Blood News and Research

RSS

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

Federal aid for lead cleanup is receding. That’s a problem for cash-strapped cities.

Tighter regulations and an influx of federal money in recent years have helped communities across the U.S. initiate efforts to clean up lead contamination in soil, drinking water, and older homes.

3 Mar 2026

Inflammatory signals from vesicles increase cancer cell aggressiveness and invasiveness

Pro-inflammatory M1 macrophages involved in immune responses accelerate the progression of melanoma through the extracellular vesicles they secrete, a recent study from the University of Eastern Finland shows. The findings were published in Cell Communication and Signaling.

3 Mar 2026

Puberty reshapes DNA to worsen or reverse insulin resistance

This study uncovers epigenetic changes during puberty that correlate with insulin resistance, offering insights into childhood obesity and metabolic risk.

3 Mar 2026

UCF researcher explores insulin signaling as new target for diabetic neuropathy

Neuropathy – chronic pain, numbness and tingling in the hands and feet – is a challenging fact of life for many patients with Type 1 diabetes.

2 Mar 2026

Hormone fluctuations influence perceived effort during intense workouts

Female sex hormones estrogen and progesterone fluctuate monthly across the menstrual cycle, affecting moods and energy levels.

2 Mar 2026

Global breast cancer burden rising fastest in low-income countries

Despite recent advancements in breast cancer treatments, new breast cancer cases in women are predicted to rise by a third globally from 2.3 million in 2023 to more than 3.5 million in 2050.

2 Mar 2026

Weight-loss drugs may reduce heart damage after heart attack

Weight-loss (GLP-1 mimicking) drugs may help prevent further tissue damage following a heart attack, significantly reducing the risk of further life-threatening complications that affect up to half of all patients, according to a new study led by the University of Bristol and University College London.

2 Mar 2026

Study reveals hydration energetics as key to nanoparticle performance in medicine

Researchers at Arizona State University have uncovered a key scientific principle that governs how what's coated on the surfaces of engineered nanoparticles may ultimately control how they work in our bodies.

2 Mar 2026

High-dose curcumin fails to produce lasting gut-microbiome changes in IBD patients

In an open-label study of 29 men, including patients with ulcerative colitis and Crohn’s disease in remission, 6 g per day of curcumin for eight weeks led to modest, transient shifts in gut microbiota composition without sustained restructuring. Despite achieving high fecal concentrations and minimal systemic bioavailability, curcumin did not produce durable microbiome changes, and disease activity scores remained stable.

2 Mar 2026

COVID-19 ARDS survivors face lasting disability and high late mortality, researchers report

In this single-center ambispective cohort of 283 Polish patients with COVID-19–related ARDS requiring invasive mechanical ventilation, cumulative mortality reached 44.5% at four years after ICU admission. Among survivors, substantial proportions reported persistent functional limitations, insomnia, fatigue, and reduced quality-adjusted life years.

2 Mar 2026

Low‑dose oral lithium may help slow the decline of verbal memory, trial suggests

Lithium-a decades-old treatment for bipolar disorder-may hold potential neuroprotective benefits beyond mood stabilization.

2 Mar 2026

New research initiative aims to predict and prevent diseases before they start

What if doctors could tell you a disease was coming years before you felt a single symptom-and stop it in its tracks? That is the goal of a sweeping new research initiative launched by the Icahn School of Medicine at Mount Sinai in collaboration with the Uniformed Services University of the Health Sciences (USU) and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF).

2 Mar 2026